Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

Combination treatment with cadonilimab and lenvatinib can produce responses in patients with advanced endometrial cancer.

Interestingly, CTLA-4 knockout mice and mice that lack expression of CTLA-4 just in T REG develop fatal, early-onset lymphoproliferative disease. 1,4 In addition, expression and signaling of CTLA ...

Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called ...

Individually, colistin decreases the effect of anti-CTLA-4 therapy in MCA205 tumors, while ampicillin, metronidazole, and vancomycin decrease responses to anti-PD-L1 therapy in MC38 tumors.

Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a risk of new onset psoriasis.

From these data, the researchers discovered that patients in the PD-1 blockade group, who were treated with a CTLA-4 blockade in prior cancer therapy outside of the study, had a dulled immune response ...

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs) found that patients responded better to a combination of two ...

multifunctional Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1) in combination with MiNK Therapeutics’ agenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy ...

Safety and efficacy of FGFR inhibitors in urothelial carcinoma: A systematic review and meta-analysis. Efficacy and safety of tislelizumab (T) combined with gemcitabine and cisplatin (GC) for patients ...